hotspot -WSS

hotspot

author：knowledge 2025-09-30 12:11:02 - browse：9

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Cancer cells are shown to suck energy source from immune cells

WSS

Peter Marks talks Operation Warp Speed for Rare Diseases

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Female surgeons have lower rates of long

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Nick Jonas talks about managing diabetes along with his career

Researchers CRISPR chickens in bid to protect them from bird flu

leisure time

hotspot

hotspot

At least 13 dead in Texas as scorching temps continue

How should state employee insurance handle Wegovy?

Alkermes shareholders re

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Bristol, Sangamo, Gilead, and more

In Memoriam: Notable people who died in 2023

Nick Jonas talks about managing diabetes along with his career

Guidelines to prevent youth baseball injuries need more muscle

UCLA team creates talking throat patch for voice disorders

leisure time

WuXi out of biotech trade group, U.S. and China relations to blame

Amid AI frenzy, a top HHS official's quest to create safeguards

UCLA team creates talking throat patch for voice disorders

HHS secretary Becerra pressed on Change HealthCare cyberattack

Boston's new lab space is opening empty

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

explore

focus

explore

Wikipedia